4-[(E)-2-(dimethylamino)ethenyl]-6-[(3-methylphenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile | 1208170-19-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-[(E)-2-(dimethylamino)ethenyl]-6-[(3-methylphenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile
• 英文别名: 4-[(E)-2-(dimethylamino)ethenyl]-6-(3-methylanilino)-2-methylsulfanylpyrimidine-5-carbonitrile
• CAS: 1208170-19-7
• 化学式: C₁₇H₁₉N₅S
• 分子量: 325.437
• InChiKey: WZUNWTYKNHBONC-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[(E)-2-(dimethylamino)ethenyl]-6-[(3-methylphenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile 在 盐酸 、 水 、 氢溴酸 、 溶剂黄146 作用下， 反应 1.83h， 生成 4-[(3-methylphenyl)amino]-2-(methylthio)pyrido[4,3-d]pyrimidin-5(6H)-one
  参考文献：
  名称：

  一种高效实用的2,4-取代的吡啶并[4,3 - d ]嘧啶-5（6 H）-one的合成方法

  摘要：

  我们描述了2,4-取代的吡啶并[4,3- d ]嘧啶-5（6 H）-ones的有效合成，其中涉及酸促成氰基烯胺15的环化反应，从而提供2,4-双-硫代甲基吡啶基并[4,3- d ]嘧啶-5（6 ħ） -酮17，为关键中间体。通过广泛的苯胺选择性置换4-甲硫基，然后氧化2-甲硫基并随后被胺取代，使得能够合成各种2,4-二取代的吡啶并[4,3- d ]嘧啶- 5（6 H）-个。

  DOI：

  10.1016/j.tetlet.2019.151312
• 作为产物：
  描述：

  4-氯-6-甲基-2-(甲硫基)嘧啶-5-甲腈 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-[(E)-2-(dimethylamino)ethenyl]-6-[(3-methylphenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile
  参考文献：
  名称：

  一种高效实用的2,4-取代的吡啶并[4,3 - d ]嘧啶-5（6 H）-one的合成方法

  摘要：

  我们描述了2,4-取代的吡啶并[4,3- d ]嘧啶-5（6 H）-ones的有效合成，其中涉及酸促成氰基烯胺15的环化反应，从而提供2,4-双-硫代甲基吡啶基并[4,3- d ]嘧啶-5（6 ħ） -酮17，为关键中间体。通过广泛的苯胺选择性置换4-甲硫基，然后氧化2-甲硫基并随后被胺取代，使得能够合成各种2,4-二取代的吡啶并[4,3- d ]嘧啶- 5（6 H）-个。

  DOI：

  10.1016/j.tetlet.2019.151312

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010019637A1

  公开（公告）日：2010-02-18

  The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

  这项发明涉及吡啶并[4,3-d]嘧啶-5(6H)-酮衍生物。具体而言，该发明涉及符合以下式(I)的化合物，其中R1、R2、R3和R4如下所定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于ACG激酶持续活化而表现出的疾病，如癌症，尤其是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• CHEMICAL COMPOUNDS
  申请人：Atkinson Francis Louis

  公开号：US20110136838A1

  公开（公告）日：2011-06-09

  The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R 1 , R 2 , R 3 , and R 4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及吡啶并[4,3-d]嘧啶-5(6H)-酮衍生物。具体而言，本发明涉及以下式I的化合物：其中R1、R2、R3和R4如下所定义。本发明的化合物是PDK1的抑制剂，可用于治疗由恒定活化的ACG激酶所表征的疾病，例如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制PDK1活性和治疗与其相关的疾病的方法。
• Chemical compounds
  申请人：Atkinson Francis Louis

  公开号：US08383635B2

  公开（公告）日：2013-02-26

  The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及吡啶并[4,3-d]嘧啶-5(6H)-酮衍生物。具体而言，本发明涉及以下式子I的化合物：其中R1、R2、R3和R4的定义如下。本发明的化合物是PDK1的抑制剂，可用于治疗由恒定激活的ACG激酶引起的疾病，如癌症，更具体地是乳腺癌、结肠癌和肺癌。因此，本发明进一步涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制PDK1活性和治疗与之相关的疾病的方法。
• US8383635B2
  申请人：——

  公开号：US8383635B2

  公开（公告）日：2013-02-26